Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTalha MunirPSPaolo SportolettiKYKeri Yang

Discussion

Loading...

Member takes

Overview

Estimation reveals zanubrutinib prevents atrial fibrillation in B-cell malignancies, indicating improved cardiovascular safety over ibrutinib.

Key Points

  • Estimate the number of patients needed to treat with zanubrutinib to prevent one atrial fibrillation event compared to ibrutinib and acalabrutinib.
  • Used a two-step approach to calculate the baseline incidence of atrial fibrillation with zanubrutinib.
  • Derived data from a safety analysis pooling results from ten clinical trials.
  • Applied odds ratios from existing literature to determine risk differences between zanubrutinib and other BTK inhibitors.
  • Estimated number needed to treat with zanubrutinib versus ibrutinib is 11, preventing one atrial fibrillation event.
  • For acalabrutinib, 24 patients needed to treat with zanubrutinib to avoid one atrial fibrillation event.

Cite This Study

Munir et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1cchttps://doi.org/10.1182/blood-2025-8024
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib2024 · 21 citations
  2. 2Risk of non-fatal MACE in patients treated with zanubrutinib and acalabrutinib: a propensity-matched analysis2026
  3. 3Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  4. 4Cardiovascular Risk of First and Second Generation Bruton’s Tyrosine Kinase Inhibitors: A Systematic Review and Network Meta-Analysis2026
  5. 5Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study2026